Molecular imaging of metabolism in cancer metastasis by Pouliot,N & Denoyer,D
		
 
 
 
 
 
 
 
 
 
This is the published version 
 
Pouliot,N and Denoyer,D 2014, Molecular imaging of metabolism in cancer 
metastasis, Cancer forum, vol. 38, no. 2, pp. 124-128. 
 
 
 
 
 
 
Available from Deakin Research Online 
 
http://hdl.handle.net/10536/DRO/DU:30071623	
	
	
	
	
	
	 	
Reproduced with the kind permission of the copyright owner 
	
 
 
 
 
 
 
Copyright: 2014, Cancer Council Australia 
CancerForum    Volume 38 Number 2 July 2014124
FORUM
Extensive metabolic reprogramming — a ‘hallmark of 
cancer’ — contributes to progression and metastasis.1,2 
Cancer cells often display a high rate of glucose 
consumption, even under oxygen-rich conditions, a 
process termed aerobic glycolysis or ‘Warburg effect’.3 
Warburg postulated that increased energy production by 
aerobic glycolysis in cancer cells was a consequence of 
impaired mitochondrial oxidative metabolism.3,4 However, 
it is now evident that tumours rarely exhibit mitochondrial 
defects and that most cancer cells still rely on oxidative 
phosphorylation to produce the majority of their energy, 
although this varies considerably between cancer types 
and sites of metastasis.5-8 Moreover, aerobic glycolysis 
is not exclusive to tumour cells, but is also a common 
feature of proliferative normal cells.9-11 The current view is 
that the primary function of elevated aerobic glycolysis is 
to generate biomass by diverting glycolytic intermediates 
towards the biosynthesis of macromolecules (nucleotides, 
lipids, proteins) required for rapidly proliferating tumour cells 
(ﬁ gure 1).12  An alternative model of cancer metabolism 
called the ‘reverse Warburg effect’ has been described 
more recently. In this model, glycolytic stromal cells 
under oxidative stress generate lactate, ketone bodies, 
glutamine and fatty acids that are taken up by metastatic 
tumour cells to generate energy through the oxidative 
mitochondrial metabolism.13-15 While this phenomenon 
may have relevance to the anti-tumour effect of natural 
antioxidants,16 more work is required to clarify how it can 
be targeted in metastatic disease.
Increased amino acid consumption resulting from 
overexpression of cell surface transporters in tumour 
cells provides an alternative to glucose.17-19 Most notably, 
glutamine is utilised as a source of nitrogen and carbon to 
generate biosynthetic components and for mitochondrial 
metabolism, essential for growth, proliferation and 
survival (ﬁ gure 1). This feature has been exploited for 
tumour imaging by positron emission tomography (PET) 
as described below.19, 20 Alterations in lipid biosynthetic 
pathways also have been described in cancer.21,22 
Unlike most normal cells, tumour cells reactivate de 
novo lipid synthesis.23,24 Fatty acid synthesis contributes 
to many aspects of transformation, including survival 
under oxidative and energy stress, maintenance of high 
glycolytic rate, growth and proliferation (ﬁ gure 1).22 Among 
other alterations, the expression of fatty acid synthase, an 
enzyme essential for fatty acid synthesis, is increased in 
several cancers including breast and prostate tumours.25,26
Perhaps the most signiﬁ cant development in recent years 
is the realisation that metabolic reprogramming is intimately 
linked to oncogenic signalling.2,27,28 Activation of oncogenic 
pathways (PI3 kinase/AKT, Ras, Src, B-Raf and Myc), or 
the loss of tumour suppressors (p53 or PTEN), increases 
glycolysis by upregulating the expression of glucose 
transporters and/or several of the glycolytic enzymes.2,29-31 
Myc promotes mitochondrial metabolism of glutamine 
by increasing the expression of ASCT2 transporters 
and glutaminases.12 Induction of the transcription factor 
HIF-1 under hypoxia leads to increased expression of 
fatty acid synthase, thereby promoting lipogenesis for 
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membrane formation and energy storage.22 PI3 kinase/
AKT signalling can activate ATP-citrate lyase, which 
converts cytoplasmic citrate into acetyl-CoA to promote 
lipid synthesis.2 Interestingly, recent evidence indicates 
that interactions between metabolic and oncogenic 
pathways are bi-directional.  For example, high glucose 
concentration or overexpression of FASN is sufﬁ cient to 
trigger the activation of oncogenic pathways and induce a 
malignant-like phenotype in mammary epithelial cells.32,33 
The characterisation of cooperative interactions between 
metabolic and oncogenic has identiﬁ ed several key 
molecular targets for diagnostic imaging and/or therapy 
(ﬁ gure 1) and prompted the development of several 
metabolic inhibitors, many of which are already under pre-
clinical evaluation.31,34
Metabolic heterogeneity and metastasis
The metabolic activity of tumours is greatly inﬂ uenced by 
their microenvironment. This implies not only that tumours 
from different tissues display different metabolic proﬁ les, 
but also that the metabolic activity of metastases from the 
same tumour may differ depending on the site of metastatic 
lesions.  Evidence for this is emerging. Facilitative sugar 
transporters (GLUTs) that mediate transport of glucose 
(and other sugars) across the plasma membrane, are 
often deregulated in cancer and their expression is often 
correlated with poor prognosis.29,35-37 However, the extent 
to which speciﬁ c transporters are upregulated depends 
on the tumour type and is inﬂ uenced by various extrinsic 
factors such as glucose concentration, inﬂ ammation and 
the speciﬁ c microenvironment of the primary tumour 
or metastasis.38-40 For instance, primary lung cancer is 
associated with increased GLUT1 expression compared 
to normal lung tissue, whereas liver metastases show 
enhanced GLUT3 and GLUT5 expression.39 A study 
examining the expression pattern of sugar transporters 
in over 200 tumour samples by immunohistochemistry 
revealed a strong upregulation of GLUT1, GLUT2 and 
GLUT5 in breast cancer compared to normal breast 
tissues.38 Increased expression of the high afﬁ nity fructose 
transporter, GLUT5, indicates that some breast tumours 
may utilise fructose as an energy source in addition to 
glucose. These ﬁ ndings may have important diagnostic 
(e.g. PET-imaging of fructose analogues) and therapeutic 
implications as suggested by the authors.38 In contrast 
to breast and lung tumours, prostate tumours show lack 
or decreased expression of most GLUTs, an observation 
consistent with their greater reliance on fatty acid synthesis 
and glutaminolysis for growth and the poor imaging 
sensitivity of 18F-FDG in these tumours.20,38,41
The link between metabolism and metastatic progression 
extends beyond elevated sugar transporter expression. 
Immunohistochemical and differential expression analysis 
of metabolic genes in metastatic pancreatic cancers 
revealed increased expression of several genes involved 
in aerobic glycolysis in primary tumours and site-speciﬁ c 
overexpression of GLUT1, pyruvate kinase M2 and 
hexokinase-2 proteins in metastatic lesions.8 Similarly, 
unique alterations in multiple metabolic pathways have 
been identiﬁ ed in breast cancer brain metastatic variant 
cells compared to bone metastatic variant cells.42 Brain 
metastatic variants were characterised by increased 
expression of enzymes involved in glycolysis, TCA cycle, 
and oxidative phosphorylation pathways in addition to 
the activation of the pentose phosphate pathway and 
the glutathione system. The authors proposed that these 
Figure 1: Schematic of key metabolic pathways in cancer cells.
Alterations in glycolysis, through the overexpression of 
glucose transporters and several glycolytic enzymes, lead 
to an increased energy production and to the redirection 
of intermediate metabolites towards the pentose phosphate 
pathway for the synthesis of nucleotides, proteins and lipids. 
Metabolic reprogramming also involves alterations in lipid 
metabolism, mainly due to the increased expression/activity 
of enzymes responsible for de novo fatty acid synthesis. 
Enhanced accumulation of amino acids is also essential for 
cancer cell proliferation. Glutamine transfers its nitrogens to 
intermediate metabolites of nucleotide and protein synthesis. Its 
deamination by glutaminases produces glutamate that is further 
processed to form glutathione, the major cellular antioxidant 
and α-ketoglutarate to replenish the TCA cycle (anaplerosis) 
for energy production and fatty acid synthesis.  Many of the 
enzymes (round yellow boxes) and transporters (square blue 
boxes) regulating metabolism are modulated by oncogenic 
signalling (e.g. Myc, Ras, p53) and are potential targets for 
therapy and molecular imaging. PET-probes used in the clinic 
or still in pre-clinical development are shown in red. Plain arrows 
denote a one-step reaction while dashed arrows denote a multi-
step reaction. HK2 = hexokinase 2; PKM2 = pyruvate kinase M2; 
LDH = lactate dehydrogenase; PDH = pyruvate dehydrogenase; 
IDH = isocitrate dehydrogenase; GLS = glutaminase; ACL = 
ATP-citrate lyase; FASN = fatty acid synthase; CK = choline 
kinase; GLUT = glucose transporters; MCT = monocarboxylate 
transporters; LAT1 = system L amino acid transporters; ASCT2 
= systeme ASCT glutamine transporters; XC
- = system XC
- 
glutamate transporters; 18F-FDG-6-P = 18F-FDG-6-phosphate; 
Glucose-6-P = glucose-6-phosphate; PPP = pentose phosphate 
pathway; AcCoA = acetyl CoA; α-KG = α-ketoglutarate; OAA = 
oxaloacetate; OXPHOS = oxidative phosphorylation; TCA cycle 
= tricarboxylic acid cycle; Gln = glutamine; 18F-Gln = 18F-labelled 
glutamine analogues; Glu = glutamate; 18F-Glu = 18F-labelled 
glutamate analogues; GSH = glutathione; AA = amino acids; 18F-
AA = 18F-labelled amino acid analogues; P-choline = phospho-
choline.
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changes could reﬂ ect a predisposition or bioenergetics 
adaptation of tumour cells to the brain microenvironment 
that contribute to their survival and growth in brain. It is not 
clear from this study whether this metabolic reprogramming 
is characteristic of all or only a subtype of brain-metastatic 
tumours. Breast cancer is a heterogeneous disease, with at 
least two molecular subtypes having high afﬁ nity for brain, 
the triple negative and HER2+ve subtypes.43 Others have 
reported that HER2+ve tumours are more glutaminolytic, 
whereas triple negative tumours are more glycolytic or 
‘Warburg-like’.44,45
A similar association between increased lipid metabolism 
and metastasis has been reported.46-49  Lipid accumulation 
in brain metastatic lesions from melanoma, lung, colorectal 
and breast tumours was correlated with areas of necrosis.46 
In another study using a pre-clinical model of osteosarcoma 
metastasis to lung, increased lipid metabolism was 
correlated with the development of metastatic lesions.47 
Interestingly, ovarian cancers, which have a high propensity 
for metastasis to the adipocyte-rich omentum, can coerce 
adipocytes to sustain their bioenergetics requirements and 
rapid growth in this tissue via direct transfer of lipids from 
adipocytes to ovarian cancer cells.49 Similar mechanisms 
may operate in metastatic endometrial, prostate and 
breast tumours.50-52 Collectively, these studies highlight 
the metabolic heterogeneity between tumours and 
metastases, which provides tremendous diagnostic 
and therapeutic opportunities. However, if the goal is 
to translate these ﬁ ndings into personalised therapies, 
a major challenge ahead will be to deﬁ ne the metabolic 
proﬁ les speciﬁ c to each tumour type and their site-speciﬁ c 
metastases.
Molecular imaging of tumour metabolism
Metabolic imaging non-invasively measures the functional 
state of tumours and metastases, and provides a mean 
by which to rapidly evaluate tumour response to therapy, 
resistance to a given treatment or even to predict treatment 
response. Thus, imaging of metabolism has high potential 
to improve the clinical management of patients. Several 
imaging modalities that take advantage of the increased 
metabolic activity observed in cancer cells have been 
implemented in the clinic or are in pre-clinical development. 
These include PET, single photon emission computerised 
tomography and magnetic resonance spectroscopy. 
The clinical use of single photon emission computerised 
tomography and magnetic resonance spectroscopy in 
cancer patients has been reviewed elsewhere.20,53 Here, 
we focus on the clinical applications and limitations of 
current radiotracers and recent advances in the ﬁ eld of 
PET imaging.
Imaging of glucose metabolism
The ﬁ rst and most commonly used probe developed 
for imaging tumour metabolism is the glucose analogue 
ﬂ uorodeoxyglucose radiolabelled with the positron 
emitter ﬂ uor-18 (18F-FDG). The transport of 18F-FDG via 
glucose transporters directly reﬂ ects the cellular use of 
glucose. However, unlike glucose, phosphorylation of 
18F-FDG by hexokinase produces 18F-FDG-6 phosphate, 
which cannot be further metabolised and therefore is 
trapped and accumulates in cells. Clinical studies on 
lymphomas and solid tumours have demonstrated the 
prognostic value of 18F-FDG for the early assessment of 
tumour response to conventional therapies.20,54 Therapy-
induced changes in glycolysis occur as early as a few 
hours following treatment, and well before any detectable 
changes in tumour size. Therefore, 18F-FDG uptake informs 
on the suitability of a chosen therapeutic intervention and 
allows rapid identiﬁ cation of non-responders who could 
beneﬁ t from alternative interventions. Thus, 18F-FDG is 
increasingly utilised as a non-invasive marker in clinical 
studies, validating the efﬁ cacy of new therapies for which 
no reliable biomarkers are currently available (e.g. B-Raf 
inhibitors for melanoma, c-Kit inhibitors for gastrointestinal 
stromal tumours and EGFR inhibitors for non-small cell 
lung cancers).55-57 Similarly, 18F-FDG could be a valuable 
marker of efﬁ cacy for new drugs targeting glycolysis or 
mitochondrial metabolism.
However, 18F-FDG suffers from some limitations. Its 
sensitivity is low for the detection of micrometastases 
from breast cancer and melanoma.41 Moreover, due to 
the high glycolytic activity in the brain, accumulation of 
18F-FDG hinders the detection of gliomas or metastases in 
this organ.20  Areas of inﬂ ammation are also 18F-FDG avid. 
Therefore, despite the rapid therapy-induced changes in 
glucose metabolism, response to chemo or radiotherapy 
is usually monitored four to six weeks after the end of 
treatment to avoid false-positives resulting from therapy-
induced inﬂ ammation.41 In addition, 18F-FDG is only weakly 
taken up and is a poor marker of metabolic activity in 
tumours that rely more heavily on fatty acid synthesis and 
glutaminolysis to grow (e.g. prostate carcinoma).20,41
Imaging of lipid metabolism
Changes in lipid metabolism provide an alternative for 
molecular imaging of tumours that are difﬁ cult to visualise 
with 18F-FDG, such as gliomas, prostate and breast 
cancers.41 Most commonly used markers of phospholipid 
biosynthesis are 11C- and 18F-choline and analogues. The 
speciﬁ city of choline-based tracers for cancer cells is the 
consequence of increased transport and phosphorylation 
of choline due to an increased expression of choline 
kinase in transformed cells.58-60 Their low urinary excretion 
makes these tracers more effective than 18F-FDG for 
identifying patients with recurrent prostate cancer.20,61 
11C-acetate was ﬁ rst developed to image oxidative 
metabolism of the myocardium. 11C-acetate enters cells 
through monocarboxilic acid transporters before being 
converted to 11C-acetyl-CoA by acetyl-CoA synthetase. In 
the myocardium, 11C-acetyl-CoA is used by the TCA cycle 
and then released from the cells as 11C-O2. In contrast, 
cancer cells metabolise 11C-acetyl-CoA predominantly 
into lipids for membrane biosynthesis and cellular energy 
production.62  Similar to choline, acetate analogues (11C or 
18F) accumulate more efﬁ ciently than 18F-FDG in prostate 
tumours and are useful tracers for detection of disease 
recurrences. Recently, 11C-acetate has shown potential as 
a non-invasive biomarker to monitor therapy response to 
orlistat, a fatty acid synthase inhibitor.62
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Imaging of amino acid metabolism
Cancer cells increase their amino acid consumption to 
accommodate their biosynthetic needs. Hence, amino 
acid-based tracers are potential alternatives to 18F-FDG. 
Amino acids are internalised via plasma membrane 
transporters, including systems L (leucine-preferring, 
LAT), A (alanine-preferring), ASCT (alanine-serine-
cysteine-preferring) and XC
- (cytine/glutamate exchange 
transporter). Increased expression of LAT1, ASCT2 and 
XC
- have been associated with cancer progression and 
poor prognosis in gliomas, lung, prostate and colon 
carcinomas, leading to the suggestion that labelled amino 
acid analogues could be valuable non-invasive prognostic 
markers for these malignancies.17, 63 Research over the 
past decades has focused mainly on LAT1 substrates.63,64 
These have the advantage of crossing the blood brain 
barrier and are weakly retained in the normal brain, and 
thus provide an accurate visualisation of brain lesions.63 
However, the clinical use of amino acid-based tracers 
for imaging extracranial solid tumours is limited by their 
relatively low speciﬁ city compared to 18F-FDG.
Glutaminolysis metabolism is increasingly recognised 
as a promising target for cancer therapy.18  Surprisingly, 
glutamine-based tracers are still in their early phase of 
development.65, 66 This stems in part from the fact that 
11C- and 13N- labelled glutamine have short half-lives, are 
rapidly metabolised, and their metabolites are excreted 
from the cells, making their use as imaging agents difﬁ cult. 
In addition, labelling glutamine/glutamate with the longer-
lived isotope 18F is technically challenging. This has been 
addressed in part with the development of the glutamine 
analogue 18F-(2S,4R)4-Fluoroglutamine (18F-4FGLN) which 
has excellent tumour targeting properties in preclinical 
models of glioblastomas and mammary tumours.65,67 
While 18F-4FGLN has yet to be tested in the clinic, pre-
clinical data suggest that it could be useful in patients 
with tumours that are addicted to glutamine and sensitive 
to therapies targeting glutamine metabolism, such as 
tumours carrying N-Myc ampliﬁ cation or HER2+ve breast 
cancer.45,68
Labelled glutamate analogues, including (4S)-4-(3-18F-
ﬂ uoropropyl)-L-glutamate (18F-FSPG or BAY 94-9392) and 
18F-(2S,4R)4-Fluoroglutamate (18F-4FGLU) have also been 
evaluated for PET imaging.66,69 18F-FSPG was well tolerated 
in patients and had a similar tumour-to-background 
ratio to 18F-FDG in a pre-clinical model of hepatocellular 
carcinoma, but unlike 18F-FDG, exhibited low accumulation 
in inﬂ ammatory lesions.69,70 Comparison of the glutamine 
analogue 18F-4FGLN and its glutamate counterpart 
18F-4FGLU, showed that both tracers have potential as 
tumour imaging agents for glioblastomas and prostate 
cancers.66 However, while glutamine and glutamate 
belong to the same metabolic pathway, 18F-4FGLN is 
taken up by ASCT2 transporters, rapidly converted to 
various metabolites and a large proportion is incorporated 
into proteins.66 In contrast, 18F-4FGLU enters cells via 
system XC
- and is not metabolised nor incorporated into 
the protein fraction.66 Therefore, 18F-glutamine analogues 
could be used to identify tumours that consume glutamine 
as an energy source and 18F-glutamate analogues to 
assess detoxiﬁ cation potential mediated by glutathione, 
synthesised from glutamate.65,66,69 One possible limitation 
of 18F-4FGLN and 18F-4FGLU is their low penetration 
through the blood brain barrier.66 Whether this will impede 
detection of brain lesions remains to be investigated in 
pre-clinical models of brain tumours and in patients.
Conclusion and perspectives
Metabolic alterations in cancer provide exciting new 
therapeutic opportunities for this often fatal disease. 
PET imaging is an integral part of cancer diagnosis and 
treatment. Advances with the design of new radiotracers 
will contribute to the clinical translation of anti-metabolic 
drugs currently in development. However, the apparent 
metabolic heterogeneity of tumours and metastases 
poses a signiﬁ cant challenge with regard to the selection 
of best treatment and imaging modalities for speciﬁ c 
tumour type and metastatic site. While 18F-FDG remains 
the gold standard for imaging of glycolytic tumours, 
other radiotracers are required to overcome some of its 
limitations, particularly in tumours that rely on alternative 
metabolic pathways for growth. The most promising 
new tracers currently in development are glutamine 
and glutamate analogues. Whether these tracers, alone 
or in combination with 18F-FDG, could provide more 
accurate detection of metastatic spread should be 
further investigated. Currently, most radiotracers only 
reﬂ ect the accumulation of nutrients due to increased 
transporter expression. Since many metabolic alterations 
involve changes in the expression or activity of metabolic 
enzymes, efforts should be put towards developing more 
speciﬁ c probes for these enzymes.
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